Stonepine Capital Management LLC Grows Stake in Aytu BioPharma, Inc. (NASDAQ:AYTU)

Stonepine Capital Management LLC increased its holdings in Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 500,958 shares of the company’s stock after buying an additional 28,489 shares during the period. Aytu BioPharma accounts for approximately 0.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 25th largest holding. Stonepine Capital Management LLC owned approximately 0.08% of Aytu BioPharma worth $1,177,000 at the end of the most recent quarter.

Separately, Armistice Capital LLC bought a new stake in shares of Aytu BioPharma during the 2nd quarter valued at about $736,000. Institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Price Performance

Shares of NASDAQ AYTU traded up $0.03 during midday trading on Wednesday, hitting $1.63. 15,797 shares of the company’s stock were exchanged, compared to its average volume of 22,809. The company has a quick ratio of 0.80, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The business’s fifty day moving average price is $2.07 and its two-hundred day moving average price is $2.53. Aytu BioPharma, Inc. has a 12-month low of $1.41 and a 12-month high of $3.45.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.37). Aytu BioPharma had a negative return on equity of 21.89% and a negative net margin of 8.28%. The company had revenue of $17.98 million during the quarter.

Aytu BioPharma Profile

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.